KYMR — Kymera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815442 ·
Last close
$103.40
Market Cap
$8.51B
52W High
$130.05
52W Low
$69.48
ADV30
1,045,440
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 34,365,000 | — | -84,154,000 | -69,234,000 | 1,669,016,000 | 144,090,000 | 129,379,000 |
| Dec 2025 | 2,870,000 | — | -97,896,000 | -86,981,000 | 1,742,812,000 | 357,011,000 | 163,148,000 |
| Sep 2025 | 2,764,000 | — | -88,666,000 | -82,175,000 | 1,102,044,000 | 112,949,000 | 155,786,000 |
| Jun 2025 | 11,476,000 | — | -84,557,000 | -76,614,000 | 1,131,068,000 | 335,816,000 | 159,588,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-242,581,000
Investing CF
$-712,516,000
Financing CF
$1,009,224,000
CapEx
$-1,416,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.57
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,135,195,000
Inventory
—
Receivables
—
ST Investments
$506,839,000
EBIT TTM
$-314,647,000
Pretax Income TTM
$-315,004,000
Interest Exp TTM
$357,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$51,476,000
EBITDA
$-348,584,992
Free Cash Flow
$-139,262,368
Enterprise Value
$7,934,974,464
Total Cash
$650,929,024
Total Debt
$80,469,000
Shares Out
82,257,588
Trailing EPS
$-3.58
Book Value
$18.73
ROE
-27.1%
ROA
-17.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 39,211,000 | -345,544,000 | -311,351,000 | 1,742,812,000 | 163,148,000 | — | -232,891,000 |
| Dec 2024 | 47,072,000 | -256,710,000 | -223,858,000 | 978,035,000 | 142,416,000 | — | -194,501,000 |
| Dec 2023 | 78,592,000 | -165,530,000 | -146,962,000 | 575,759,000 | 180,788,000 | — | -102,826,000 |
| Dec 2022 | 46,826,000 | -161,256,000 | -154,808,000 | 603,134,000 | 112,983,000 | — | -153,085,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $8.54B | $41.40 | — |
| APGE | Apogee Therapeutics, Inc. | $8.27B | $134.09 | — |
| RGEN | REPLIGEN CORP | $7.96B | $141.01 | — |
| IMVT | Immunovant, Inc. | $7.93B | $38.62 | — |
| PCVX | Vaxcyte, Inc. | $7.81B | $54.08 | — |
News headlines (Yahoo Finance, 1h cache)
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
2026-07-30 13:38 · Yahoo
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More
2026-07-30 12:05 · Yahoo
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-28 20:01 · Yahoo
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
2026-07-27 20:01 · Yahoo
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
2026-07-24 15:18 · Yahoo
American Express, Biogen upgraded: Wall Street's top analyst calls
2026-07-13 13:41 · Yahoo
Kymera's CEO Sold $6 Million in Stock After a 170% Run
2026-07-12 20:57 · Yahoo
Is Kymera (KYMR) the Best Performing American Stock in June 2026?
2026-07-09 10:40 · Yahoo
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
2026-07-07 11:00 · Yahoo
Alkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors.
2026-07-03 08:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.